Browsing by Author "Altunoren, Orcun"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • No Thumbnail Available
    Publication
    The efficacy of cinacalcet in the treatment of hyperparathyroidism in turkish hemodialysis patient population
    (Türk Nefroloji Diyaliz Transplantasyon Dergisi, 2016-01-01) Altunoren, Orcun; Gungor, Ozkan; Eren, Necmi; Tanrisev, Mehmet; Hur, Ender; Turkmen, Kultigin; Yavuz, Yasemin Coskun; Sahin, Osman Zikirullah; Saglam, Funda; Turan, Mehmet Nuri; Yaprak, Mustafa; Ulutas, Ozkan; Kocyigit, Ismail; Oguz, Ayten; Ari, Elif; Ada, Sibel; Yıldız, Abdulmecit; Azak, Alper; Korkmaz, Ahmet Edip; Yavuz, Demet; Dogan, Ibrahim; Tekce, Hikmet; Sert, Mehmet; Kaya, Bulet; Bakirdogen, Serkan; Kose, Sennur; Sakaci, Tamer; Pembegul, Irem; Aytug, Ferhan; Guclu, Aydin; Akgul, Bulent; Yilmaz, Mahmut Ilker; YILDIZ, ABDULMECİT; Uludağ Üniversitesi/Tıp Fakültesi.; HIG-9032-2022
    OBJECTIVE: Cinacalcet reduces parathyroid hormone levels by increasing the sensitivity of the parathyroid gland to calcium. In this study, we firstly aimed to evaluate the efficacy of cinacalcet in Turkish hemodialysis patients.MATERIAL and METHODS: 4483 hemodialysis patients were screened and 469 patients who had used cinacalcet were included in the study. The patients were divided into 4 groups according to drug usage durations (Group 1: 3 months, Group 2: 6 months, Group 3: 9 months and Group 4: 12 months). The patients' Parathormone, Ca, P and CaxP levels at the 3rd, 6th, 9th and 12th months were compared to the start of treatment and previous months.RESULTS: The levels of Parathormone, Ca, P and CaxP significantly decreased compared to their initial levels in all groups (from 1412 pg/ml to 1222 pg/mL for Parathormone, p< 0,001) in the 3rd month. However, this reduction was not continued in the subsequent months (Parathormone: 1381 pg/ml for the 12th month).CONCLUSION: Cinacalcet may not provide adequate benefit in control of hyperparathyroidism in Turkish hemodialysis patient population.
  • Thumbnail Image
    Publication
    The longitudinal evolution of post-COVID-19 outcomes among hemodialysis patients in Turkey
    (Elsevier Science Inc, 2022-06-03) Ozturk, Savas; Turgutalp, Kenan; Arici, Mustafa; Gorgulu, Numan; Tonbul, Halil Zeki; Eren, Necmi; Gencer, Vedat; Ayli, Mehmet Deniz; Pembegul, Irem; Dolarslan, Murside Esra; Ural, Zeynep; Colak, Hulya; Ozler, Tuba Elif; Can, Ozgur; Demir, Mehmet Emin; Altunoren, Orcun; Huddam, Bulent; Onec, Kursad; Demirelli, Bulent; Aydin, Zeki; Altun, Eda; Alagoz, Selma; Ayar, Yavuz; Eser, Zeynep Ebru; Berktas, Bayram; Yilmaz, Zulfukar; Ates, Eser Uslu; Yuksel, Enver; Sahin, Gizem Kumru; Aktar, Merve; Cebeci, Egemen; Dursun, Belda; Kocak, Sibel Yucel; Yıldız, Abdülmecit; Kazan, Sinan; Gok, Mahmut; Sengul, Erkan; Tugcu, Murat; Ozturk, Ramazan; Kahvecioglu, Serdar; Kara, Ekrem; Kaya, Bulent; Sahin, Garip; Sakaci, Tamer; Sipahi, Savas; Kurultak, Ilhan; Durak, Beyza Algul; Altiparmak, Mehmet Riza; Ecder, Sabahat Alisir; Karadag, Serhat; Dincer, Mevlut Tamer; Ozer, Hakan; Bek, Sibel Gokcay; Ulu, Memnune Sena; Gungor, Ozkan; Bakir, Elif Ari; Odabas, Ali Riza; Seyahi, Nurhan; Yildiz, Alaattin; Ates, Kenan; YILDIZ, ABDULMECİT; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Nefroloji Anabilim Dalı.; HIG-9032-2022
    Introduction: Hemodialysis (HD) patients have increased risk for short-term adverse outcomes of COVID-19. However, complications and survival at the post-COVID-19 period have not been published extensively.Methods: We conducted a national, multicenter observational study that included adult maintenance HD patients recovered from confirmed COVID-19. A control HD group without COVID-19 was selected from patients in the same center. We investigated the characteristics and outcomes in the follow-up of HD patients and compare them with the non-COVID-19 group.Results: A total of 1223 patients (635 patients in COVID-19 group, 588 patients in non-COVID-19 group) from 47 centers were included in the study. The patients' baseline and HD characteristics were almost similar. The 28th-day mortality and mortality between 28th day and 90th day were higher in the COVID-19 group than non-COVID-19 group (19 [3.0%] patients vs. none [0%]; 15 [2.4%] patients vs. 4 [0.7%] patients, respectively). The presence of respiratory symptoms, rehospitalization, need for home oxygen therapy, lower respiratory tract infection, and arteriovenous (AV) fistula thrombosis was significantly higher in the COVID-19 group in both the first 28 days and between 28 and 90 days. In the multivariable analysis, age (odds ratio [OR] [95% CI]: 1.029 [1.004-1.056]), group (COVID-19 group vs. non-COVID-19 group) (OR [95% CI]: 7.258 [2.538-20.751]), and vascular access type (tunneled catheter/AV fistula) (OR [95% CI]: 2.512 [1.249-5.051]) were found as independent parameters related to 90-day mortality.Conclusion: In the post-COVID-19 period, maintenance HD patients who have had COVID-19 have increased rehospitalization, respiratory problems, vascular access problems, and high mortality compared with the non-COVID-19 HD patients.